A proposed codification of the U.S. Food & Drug Administration’s regulatory approach to allow wholesale prescription drug importation programs from Canada is the latest twist in the seemingly endless political dance over using parallel trade to address drug prices in the U.S.
The Senate Health Committee’s latest iteration of the user fee omnibus (dubbed the FDA Safety & Landmark Amendments Act or...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?